Speaker Profile
M.D., Ph.D., Chief of Stanford BMT and Cell Therapy Program, Stanford
Biography
David Miklos is a leading figure in cellular immunotherapy and central to the clinical development of CAR-T cell therapy. He led the trials supporting FDA approval of axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma and brexucabtagene autoleucel (brexu-cel) in mantle cell lymphoma. He directs one of the largest cell therapy programs in the country, and his lab identified antigen loss as the major cause of CAR-T failure and pioneered circulating tumor DNA for lymphoma minimal residual disease. His work on the biology and safe management of CAR-T continues to make the therapy more precise and durable for patients.
Session Abstract – PMWC 2027 Silicon Valley
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
